

09/914213

JC05 Rec'd PCT/PTO 23 AUG 2001
Attorney Docket No. 03037.00003

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:)	BOX PCT
)	
Lynn M. ADAMS, et al.)	National Phase Application
)	PCT/US00/04642
Serial No. Unassigned)	Filed: February 24, 2000
)	
Filed: Concurrently Herewith)	Group Art Unit: Unassigned
)	
For: ENHANCERS OF CFTR CHLORIDE)	Examiner: Unassigned
CHANNEL FUNCTION)	

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This Information Disclosure Statement is submitted for consideration by the United States Patent and Trademark Office in accordance with the duty of disclosure.

Transmitted herewith is:

- ☒ [X] A PTO 1449 form
- ☐ [] A Background Art Information Paper
- ☒ [X] A copy of each item of information listed on the PTO 1449 form
- ☐ [] Concise explanation of non-English language information
 - ☒ [X] concise explanation of relevance:
 - ☐ [] English translation of foreign language information
 - ☒ [X] English language version of foreign patent office report citing information
 - ☐ [] English language abstract(s) of foreign patent document(s)

- ☐ This application relies, under 35 U.S.C. §120, on the earlier filing date of U.S. Application Serial No. ****, filed ***. The information identified on the attached PTO 1449 form was submitted to and/or cited by the Patent and Trademark Office in this earlier application and, therefore, copies are not required to be provided in this application.

1. ☒ This Information Disclosure Statement is filed before the later of:
- ☐ three months from the filing date of this national application;
 - ☒ three months from the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or
 - ☐ the mailing date of a first office action on the merits.

In accordance with 37 CFR 1.97(b), no fee is required.

2. ☐ This Information Disclosure Statement is filed after the events noted in paragraph 1, but before either:
- ☐ a final action under 37 CFR 1.113, or an action that otherwise closes prosecution,
 - ☐ a Notice of Allowance under 37 CFR 1.311.

In accordance with 37 CFR 1.97(c), also enclosed is

- ☐ a fee under 37 CFR 1.17(p) for \$180.00; or
- ☐ a certification as stated below.

3. ☐ This Information Disclosure Statement is filed before payment of the issue fee, but after either
- ☐ a final action under 37 CFR 1.113, or an action that otherwise closes prosecution;
 - ☐ a Notice of Allowance under 37 CFR 1.311.

In accordance with 37 CFR 1.97(d), also enclosed is:

- ☐ a certification, as stated below; and
- ☐ the IDS processing fee set forth in 37 CFR 1.17(p)(1) in the amount of \$180.00.

Certification

The undersigned states:

☐ Each item of Information contained in this Information Disclosure Statement was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement; or

☐ No item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign Patent Office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing date of this Information Disclosure Statement.

TOTAL FEES: \$

☐ A check for the amount of the above indicated TOTAL FEES is attached.

☐ Please charge Deposit Account No. 19-0733 in the amount of \$.

☐ A check for \$ is enclosed.

☒ No fee is required.

☐ Please charge or credit Deposit Account No. 19-0733 for an deficiency or overpayment associated with this Information Disclosure Statement.

09/914213

JC05 Rec'd PCT/PTO 23 AUG 2001

Attorney Docket No. 03037.00003

A duplicate copy of this sheet is enclosed for accounting purposes.

It is respectfully requested that the Examiner fully consider each item of information, initial the enclosed Form PTO-1449 in the appropriate place to indicate that the information has been considered, and return a copy of the initialed form to the undersigned in accordance with MPEP Section 609.

Respectfully submitted,

BANNER & WITCOFF, LTD.

By: *Sarah A. Kagan* (Registration No. 47,460) FOR *Sarah Kagan*
Sarah A. Kagan
Registration No. 32,141

Eleventh Floor
1001 G Street, N.W.
Washington, D.C. 20001-4597
(202) 508-9100

Dated: August 23, 2001

JC05 Rec'd PCT/PTO 23 AUG 2000

USPTO Form 1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION Sheet 1 of 1		Attorney Docket No. 03037.00003		International Serial No. PCT/US00/04642		
		Applicant(s): Lynn M. ADAMS, et al. 09/914213				
		International Filing Date: February 24, 2000			Group: Unassigned	
U.S. PATENT DOCUMENTS						
Examiner Initial	Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
FOREIGN PATENT DOCUMENTS						
Examiner Initial	Document No.	Date	Country	Class	Subclass	Translation
						YES NO
	95/25796	09/28/95	WIPO			
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)						
	ADAMS, L.M., et al: "Deletion of a negatively charged region (a.a. 817-838) from the R domain of CFTR alters PKA-dependent regulation of the CFTR channel. BIOPHYSICAL JOURNAL, vol. 74, no. 2, Part 2, February 1998 (1998-02), page A344, XP000923128					
	TASCH, JASON E. et al.: "Functional dissection of the R domain of cystic fibrosis transmembrane conductance regulator.", FEBS LETTERS, vol. 445, no. 1, 19 February 1999, pages 63-68, XP002142114					
	WINTER, MICHAEL C, et al.: "Stimulation of CFTR activity by its phosphorylated R domain." NATURE (LONDON), vol. 389, no. 6648, 1997, pp. 294-296, XP002142115					
	MA JIANJIE et al.: "Phosphorylation-dependent block of cystic fibrosis transmembrane conductance regulator chloride channel by exogenous R domain protein.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 13, 1996, pp. 7351-7356, XP002142116					
	MA JIANJIE, et al.: "Function of the R domain in the cystic fibrosis transmembrane conductance regulator chloride channel.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 44, 31 October 1997, pp. 28133-28141, XP002142117					
	COTTON, Joseph F., et al.: "Covalent modification of the regulatory domain irreversibly stimulates cystic fibrosis transmembrane conductance regulator", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 41, 1997, pp. 25617-25622, XP002142118					
	RICH, DEVRA P., et al.: "Regulation of the cystic fibrosis transmembrane conductance regulator chloride channel by negative charge in the R domain.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 27, 1993, pp. 20259-20267, XP-002142119					
EXAMINER				DATE CONSIDERED		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.						
**Copies of references not provided at the time of this submission.						